Is it aprotinin renaissance now?

Charnaia M.A.; Dement'eva I.I.; Morozov Iu.A.

doi:https://doi.org/

References:

Dement'eva I.I., CHarnaya M.А., Krotovskij А.G. i dr. Vliyanie bol'shikh doz trasilola na disfunktsiyu shuntov posle operatsij АKSH [Effect of large doses of trasylol on dysfunction of grafts after CABG]. Vserossijskij s"ezd serdechno-sosudistykh khirurgov, 8-j. M 2002(in Russian)
Dement'eva I.I., CHarnaya M.А., Morozov YU.А. i dr. Bezopasnoe ispol'zovanie antifibrinoliticheskikh preparatov v kardiokhirurgii: mif ili real'nost'? [Safe use of antifibrinolytic drugs in cardiac surgery: myth or reality?] Kardiologiya i serdechno-sosud khir 2009; 2: 6: 69-71. (in Russian)
Dement'eva I.I., CHarnaya M.А., Morozov YU.А. Sistema gemostaza pri operatsiyakh na serdtse i magistral'nykh sosudakh [Hemostatic system during operations on the heart and great vessels]. M: GEHOTАR-Media 2009; 154-210. (in Russian)
CHarnaya M.А. Patofiziologicheskie acpekty primeneniya bol'shikh doz aprotinina pri operatsiyakh s iskusstvennym krovoobrashheniem [Pathophysiological aspects of large doses of aprotinin in operations with cardiopulmonary bypass]: Аvtoref. dis. ... kand. biol. nauk. M 1993. (in Russian)
CHarnaya M.А., Morozov YU.А., Gladysheva V.G., Savost'yanova N.M. Vzaimosvyaz' mezhdu ispol'zovaniem aprotinina i razvitiem pochechnoj disfunktsii u kardiokhirurgicheskikh bol'nykh [The relationship between the use of aprotinin and the development of renal dysfunction in cardiac patients].Grudnaya i serdechno-sosud khir 2007; 1: 32-34. (in Russian)
Alderman E.L., Levy J.H., Rich J.B. et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998; 116: 716-730.
Beattie W.S., Karkouti K. The post-BART anti-fibrinolytic dilemma? J Cardiothorac Vasc Anesth 2011; 25: 3-5.
Beierlein W., Scheule A.M., Dietrich W., Ziemer G. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg 2005; 79: 2: 741-748.
Brown J.R., Birkmeyer N.J.O., O'Connor G.T. Metaanalysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115: 2801-2813.
Casati V., Bellotti F., Gerli C. et al. Tranexamic acid administration after cardiac surgery: a prospective, randomized, double-blind, placebo-controlled study. Anesthesiology 2001; 94: 1: 8-14.
De Santis S.M., Toole J.M., Kratz J.M. et al. Early postoperative outcomes and blood product utilization in adult cardiac surgery: the post-aprotinin era. Circulation 2011; 124: 62-69.
Fanashawe M.P., Shore-Lesserson L., Reich D.L. Two cases of fatal thrombosis after aminocaproic acid therapy and deep hypothermic circulatory arrest. Anesthesiology 2001; 95: 6: 1525-1527.
Ferqusson D.A., Hebert P.C., Mazer C.D. et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Eng J Med 2008; 358: 22: 2319-2331.
Fiechter B.K., Nuttall G.A., Jonson M.E. Plasma tranexamic acid concentration during cardiopulmonary bypass. Anesth Analg 2001; 92: 1131-1136.
Frumento R.J., O'Malley C.M., Bennett-Gurrevo E. Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens. Ann Thorac Surg 2003; 75: 183- 479.
Furtmüller R., Schlag M.G., Berger M. et al. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther 2002; 301: 168-173.
Grunkemeier G.L., Wu Y., Furnary A.P. Ann Thorac Surg 2009; 87: 1337-1343.
Henry D.A., Moxey A.J., Carless P.A. et al. Fnti-fibrinilytic use for minimizing perioperative allogenic blood transfusion. Cochrane Database Syst Rev 2011; 1: CD001886.
Howell N., Senanayake E., Freemantle N., Pagano D. Putting the record straight on aprotinin as safe and effective: Results from a mixed treatment metaanalysis of trials of aprotinin. J Thorac Cardiovasc Surg 2012; 1: 32.
Ishibashi N., Iwata Y., Zurakowski D. et al. Aprotinin protects the cerebral microcirculation during cardiopulmonary bypass. Perfusion 2009; 24: 99-105.
Jares M., Vanek T., Straka Z., Brucek P. Tranexamic acid reduced bleeding after off-pump coronary artery bypass grafting. J Cardiovasc Surg 2003; 44: 2: 205-208.
Karkouti K., Wijeysundera D.N., Yau T.M. et al. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 2010; 110: 1: 21-29.
Kher A., Meldrum K.K., Hile K.L. et al. Aprotinin improves kidney function and decrease tubulare cell apoptosis and proapoptotic signaling after renal ischemia-perfusion. J Thorac Cardiovasc Surg 2005; 130: 662-669.
Mangano D.T., Tudor I.C., Diezel C. The risk associated with aprotinin in cardiosurgery. N Engl J Med 2006; 354: 4: 353-365.
Martin K., Wiesner G., Breuer T. et al. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008; 107: 1783-1790.
Martin K., Knorr J., Breuer T. et al. Seizures after open heart surgery: comparison of e-aminocaproic acid and tranexamic acid. J Cardiothorac Vasc Anesth 2011; 25: 20-25.
Montes F.R., Pardo D.F., Carreño M. et al. Risk factors associated with postoperative seizures in patients undergoing cardiac surgery who received tranexamic acid: a case-control study. Ann Cardiol Anaesth 2012; 15: 6-12.
Murkin J.M., Falter F., Grantan J. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010; 110: 350-353.
Ovrum E., Am Holen E. Abdelnoor M. et al. Tranexamic acid (Cyklokapron) is not necessary to reduce loss after coronary artery bypass operations. J Thorac Cardiovasc Surg 1993; 105: 1: 78-83.
Ozier Y. Pharmacological approaches to redusing blood loss and transfusions in the surgical patient. Can J Anesth 2006; 53: 6: S21-S29.
Pleym H., Stenseth R., Wahba A. et al. Single-dose tranexamic acid reduced postoperative bleeding after coronary surgery in patients treated with aspirin until surgery. Anesth Analg 2003; 94: 4: 923-928.
Questions and answers on the review of antifibrinolytic medicines (aprotinin, aminocaproic acid and tranexamic acid). Eur Med Agency. // www.ema.europa.eu.
Saffitz J.E., Stahl D.J., Sundt T.M. et al. Disseminated intravascular coagulation after administration of aprotinin in combination with deep hypothermic circulatory arrest. Am J Cardiol 1993; 72: 1080-1082.
Sander M., Spies C.D., Martiny V. et al. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care 2010; 14: 4: R148.
Schweizer A., Hohn L., Morel D.R. et al. Aprotinin does not impair renal haemodinamics and function after cardiac surgery. Br J Anaesth 2000; 84: 16-22.
Sedrakyan A., Treasure T., Elefteriades J.A. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and metaanalysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004; 128: 3: 442-448.
Slaughter T.F., Faghih F., Greenberg C.S. et al. The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg 1997; 85: 6: 1221-1226.
Spiess B.D. Pro: The practice of cardiac anesthesia has changed after the withdrawal of aprotinin. J Cardiothorac Vasc Anesth 2010; 24: 875-878.
Tempe D.K., Hasija S. Are tranexamic acid and ε-aminocaproic acid adequate substitutes for aprotinin? Ann Cardiol Anaesth 2012; 15: 4-5.
Vonk A.B., Meesters M.I., Schats J. et al. Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery. Inter Cardiovasc Thorac Surg 2011; 12: 2: 135-139.